Anzeige
Mehr »
Dienstag, 01.07.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
1.013 Leser
Artikel bewerten:
(3)

Eviana Health Corporation: Eviana Provides Update on Details of Strategic Alternatives

TORONTO, ON / ACCESSWIRE / September 6, 2019 / Eviana Health Corporation (the "Company") (CNSX:EHC)(OTC PINK:EVNNF) is announcing the following:

Strategic Alternatives

The Board is in the process of considering its options for shareholders in connection with various strategic alternatives, including those outlined below, and is in the process of retaining suitable professional advisors in that regard. Further disclosures will be made as this process progresses.

Proposed Hostile Take-over from AgraFlora

On August 9, 2019, Agra Flora Organics International Inc. ("AgraFlora"), having previously communicated to the Board (on July 27, 2019) through a non-binding letter of intent an interest in exploring a business combination with the Company, announced that it intended to make an offer (the "AF Offer") to purchase all of the issued and outstanding common shares of the Company (the "Eviana Shares") at a price of 1.694915 AgraFlora shares (the "AF Shares") for each Eviana share (based on the offer price of $0.50 per Eviana Share and the closing price of AF Shares of $0.295 on August 9, 2019). AgraFlora has yet to formalize the AF Offer.

Proposed Private Placement and Joint Venture from Abrazen-Devolli

On August 26, 2019, Board received the signed letter of intent ("LOI") from Company Abrazen-Devolli ("Abrazen") group from Malta, outlining the intent to collaborate and enter into a proposed joint venture in regard to the production of CBD and THC possibly in Macedonia, production of CBD infused foods and beverages (using the existing facilities of Abrazen located in Kosovo), and other potential products (the "Abrazen LOI"). According to the Abrazen LOI Eviana would allow Abrazen to purchase by way of private placement CAD 4,500,000 of units of EHC at CAD $0.50 per unit consisting of one common share and one common share purchase warrant with each warrant exercisable into one common share for CAD $1.00 for two years. As a term of the investment, Abrazen would acquire the right to appoint a member to Eviana's Board, as well as its CFO and CEO.

About Eviana Health Corporation

The Company was established with the aim of delivering customized consumer health care products using natural hemp strains of cannabis sativa for cannabinoid-based topical creams, products and cosmeceutical and nutraceutical merchandise. The Company's wholly owned subsidiary, Eviana Inc., an Ontario corporation, holds certain assets in Serbia relating to the cultivation of industrial hemp plant oil for the pharmaceutical, nutraceutical and cosmeceutical industry, and has access to a significant grower/supplier of cannabinoids including two subsidiaries, Intiva Plus, d.o.o. and Eviana d.o.o.

FOR FURTHER INFORMATION PLEASE CONTACT:

Avram Adizes , CEO
Tel: (416) 301-9654

Eviana Health Corporation
info@eviana.com

This news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "would", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Forward-looking information is based on the opinions and estimates of management at the date the information is provided, and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's publicly filed disclosure. The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change, unless required by law. The reader is cautioned not to place undue reliance on forward-looking information.

SOURCE: Eviana Health Corporation



View source version on accesswire.com:
https://www.accesswire.com/558792/Eviana-Provides-Update-on-Details-of-Strategic-Alternatives

© 2019 ACCESS Newswire
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.